Willow Tree Research initiates coverage of Immunovant with a BUY rating and a $50 price target, driven by optimism about its drug IMVT-1402. The drug shows strong reduction in IgG with minimal side effects, potentially making it best-in-class, especially for treating Graves' disease. The valuation is based on expected peak sales of around $4 billion and a conservative sales multiple, valuing the company at about $10.9 billion. Immunovant has cash to operate through 2028 but may need additional non-dilutive funding as it advances late-stage trials and commercialization efforts.
Alaska Airlines has started nonstop flights between Los Angeles International Airport and Manuel Márquez de León International Airport in La Paz, Mexico. This new route enhances connectivity for U.S. travelers, especially from West Coast cities, maki...
The global livestock monitoring market is rapidly expanding due to over $55 million in recent funding and increasing regulatory demands, especially in Europe. AI technologies like computer vision, IoT sensors, and predictive analytics are transformin...
Itron reported a strong Q2 2026 with non-GAAP EPS of $1.59, beating analyst estimates by 22.31% for the fourth straight quarter. Revenue fell 7% to $562.9 million due to timing of project deployments, but annual recurring revenue rose 21% to $417 mil...
FirstEnergy Corp. will report Q2 2026 earnings on July 28, with analysts expecting EPS around $0.50 and revenue near $3.51 billion, driven by rising demand from data centers and industrial clients. The company is investing $36 billion from 2026 to 20...
Saviynt has exceeded $300 million in annual recurring revenue and grown bookings by over 80%, driven by rising demand for identity security amid AI adoption. The company launched Zuma, a new AI identity security platform that offers real-time visibil...
